Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States

Ann Hematol. 2023 Aug;102(8):2299. doi: 10.1007/s00277-023-05327-x.

¹ Yale University School of Medicine, New Haven, CT, USA. amer.zeidan@yale.edu.
² Division of Hematology, School of Medicine, University of Colorado, Aurora, CO, USA.
³ Oregon Health & Science University, Portland, OR, USA.
⁴ Bristol Myers Squibb, Princeton, NJ, USA.
⁵ SmartAnalyst Inc., New York, NY, USA.

No abstract available

Publication types